Multispecific Immune Cell Engagers for Cancer Immunotherapy

Time: 8:15 am
day: Day Two

Details:

• Immune cell engagers go beyond being bispecifics
• Addition of an anti-CD28 component enhances response
• A new HER2 T cell engager exhibits potent in vitro activity against a panel of HER2-expressing cancer models

Speakers: